All In Biotech

Drug Trial Radar · NCT06581380

JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer

A Multicenter, Randomized, Positive-Controlled, Open-label, Phase 3 Study of JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer After Platinum-based First-line Chemotherapy

Last checked: Nov 20, 2026Latest source record: Sep 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 394 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

394

Planned (sponsor's estimate)

Start

Sep 16, 2024

Primary completion

Nov 16, 2027

Study completion Apr 16, 2028

Sponsor

Lead sponsor
JenKem Technology Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to compare the efficacy and safety of JK-1201I with Topotecan in patients with relapsed extensive stage small cell lung cancer (ES SCLC).

Conditions

  • Small Cell Lung Cancer

Interventions

  • JK-1201IDrug

    JK-1201I will be administered as an IV infusion at dose of 180mg/m2 on Day 1 of each 21-day cycle.

  • TopotecanDrug

    Topotecan will be administered per drug label.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: From the date of randomization to the date of death due to any cause; Up to approximately 3.5 years.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.